{"id":3620,"date":"2018-11-15T12:51:50","date_gmt":"2018-11-15T07:21:50","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3620"},"modified":"2021-07-24T12:57:07","modified_gmt":"2021-07-24T07:27:07","slug":"the-business-cocktail-45","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-45","title":{"rendered":"Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates; Celgene\u2019s deal"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Preclinical biotech Synthorx needs a USD 100 Million IPO<\/strong><\/p>\n<p style=\"text-align: justify;\">The early-stage <strong>Synthorx<\/strong> needs <strong>USD 100 million<\/strong> <strong>IPO<\/strong>. \u00a0A while ago, La Jolla, California-based biotech got off a USD 63 million series C, but now wants a USD 100 million from an IPO to progress its pipelines of <a href=\"https:\/\/www.delveinsight.com\/report-store\/cell-wall-synthesis-inhibitor-pipeline-insight\">synthetic <\/a>cytokines, which are designed to improve the efficacy of immuno-oncology treatments without the negative side effects that sometimes come with native cytokines.<\/p>\n<p style=\"text-align: justify;\"><strong>Deerfield puts up USD 80 Million to pursue protein degradation R&amp;D <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Deerfield<\/strong> Management is setting up <strong>USD 80 million<\/strong> to fund the creation of a new Center for <strong>Protein Degradation<\/strong> at the <strong>Dana-Farber Cancer Institute<\/strong>. The goals of the project include creating a new small-molecule therapy platform that can direct and drive protein degradation by the proteasome, harnessing the complexes that cut down and clear damaged or harmful proteins from the cell.<\/p>\n<p style=\"text-align: justify;\"><strong>SVB remunerates USD 280 Million to Leerink <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Silicon Valley Bank<\/strong> parent <strong>SVB<\/strong> is remunerating<strong> USD 280 million<\/strong> to prominent life sciences investor <strong>Leerink Partners<\/strong> for creating SVB Leerink. This is a company that will deliver a complete capital markets offering. This includes debt, convertible debt and equity financing as well as advisory services, which further includes mergers &amp; acquisitions for private and public healthcare and life science companies.\u00a0SVB is already active in both tech and life sciences; its clients include around half the venture capital-backed companies in these sectors in the U.S., but collaborating with Leerink, it will give it a big gain in life sciences, particularly in research and advisory expertise.<\/p>\n<p style=\"text-align: justify;\"><strong>Celgene extends Dragonfly natural killer<\/strong> <strong>cells deal <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Celgene<\/strong> is increasing its cancer immunotherapy agreement with <strong>Dragonfly Therapeutics<\/strong>, remunerating USD 50 million up front for accessing to four more <strong>natural killer (NK)<\/strong> cell-based programs. The duo collaborated last year when Celgene pays USD 33 million to license four assets for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/blood-coagulation-factor-activators-pipeline-insight\">blood <\/a>cancers treatment.\u00a0The original four assets are designed to treat <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-myeloid-leukemia-aml-market\">acute myeloid leukaemia<\/a>, multiple myeloma and other haematological cancers, while the new four include treatments in development for solid tumours.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Preclinical biotech Synthorx needs a USD 100 Million IPO The early-stage Synthorx needs USD 100 million IPO. \u00a0A while ago, La Jolla, California-based biotech got off a USD 63 million series C, but now wants a USD 100 million from an IPO to progress its pipelines of synthetic cytokines, which are designed to improve the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3458,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1927,155,2152,2150,1349,2157,1728,2154,410,2155,2156,2151,2153,2149],"industry":[17225],"therapeutic_areas":[17235,17228,17234],"class_list":["post-3620","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-acute-myeloid-leukaemia","tag-celgene","tag-dana-farber-cancer-institute","tag-deerfield","tag-dragonfly-therapeutics","tag-haematological-cancers","tag-ipo","tag-leerink-partners","tag-multiple-myeloma","tag-natural-killer","tag-nk","tag-protein-degradation","tag-silicon-valley-bank","tag-synthorx","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates<\/title>\n<meta name=\"description\" content=\"Synthorx needs USD 100 million IPO. \u00a0A while ago, La Jolla, California-based biotech got off a USD 63 million series C, but now wants a USD 100 million...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-45\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates\" \/>\n<meta property=\"og:description\" content=\"Synthorx needs USD 100 million IPO. \u00a0A while ago, La Jolla, California-based biotech got off a USD 63 million series C, but now wants a USD 100 million...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-45\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-11-15T07:21:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"3000\" \/>\n\t<meta property=\"og:image:height\" content=\"1875\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates","description":"Synthorx needs USD 100 million IPO. \u00a0A while ago, La Jolla, California-based biotech got off a USD 63 million series C, but now wants a USD 100 million...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-45","og_locale":"en_US","og_type":"article","og_title":"Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates","og_description":"Synthorx needs USD 100 million IPO. \u00a0A while ago, La Jolla, California-based biotech got off a USD 63 million series C, but now wants a USD 100 million...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-45","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-11-15T07:21:50+00:00","article_modified_time":"2021-07-24T07:27:07+00:00","og_image":[{"width":3000,"height":1875,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-45","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-45","name":"Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-45#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-45#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma.jpg","datePublished":"2018-11-15T07:21:50+00:00","dateModified":"2021-07-24T07:27:07+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Synthorx needs USD 100 million IPO. \u00a0A while ago, La Jolla, California-based biotech got off a USD 63 million series C, but now wants a USD 100 million...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-45"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-45#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma.jpg","width":"3000","height":"1875","caption":"100 dollar bills, pills, and medicine containers"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma-300x188.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">acute myeloid leukaemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Celgene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dana-Farber Cancer Institute<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Deerfield<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dragonfly Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">haematological cancers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IPO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Leerink Partners<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">natural killer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Protein Degradation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Silicon Valley Bank<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Synthorx<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">acute myeloid leukaemia<\/span>","<span class=\"advgb-post-tax-term\">Celgene<\/span>","<span class=\"advgb-post-tax-term\">Dana-Farber Cancer Institute<\/span>","<span class=\"advgb-post-tax-term\">Deerfield<\/span>","<span class=\"advgb-post-tax-term\">Dragonfly Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">haematological cancers<\/span>","<span class=\"advgb-post-tax-term\">IPO<\/span>","<span class=\"advgb-post-tax-term\">Leerink Partners<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">natural killer<\/span>","<span class=\"advgb-post-tax-term\">NK<\/span>","<span class=\"advgb-post-tax-term\">Protein Degradation<\/span>","<span class=\"advgb-post-tax-term\">Silicon Valley Bank<\/span>","<span class=\"advgb-post-tax-term\">Synthorx<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Nov 15, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Nov 15, 2018 12:51 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"100 dollar bills, pills, and medicine containers","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3620","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3620"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3620\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3458"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3620"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3620"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3620"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3620"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}